

PROSCA'25

Global Forum on
Prostate Cancer


PROGRAMME BOOKLET

Global Forum on Prostate Cancer

5-6 December 2025

EPIC SANA Lisboa Hotel, Portugal

gu-global-forum.org



Welcome

Dear colleagues, dear friends,

Congratulations, you've made it to Lisbon, the destination of your PROSCA journey! Some say the journey is more important than the destination. We say: they are equally important. The journey with the patient case challenges was the ideal warm-up for the real workout: PROSCA 2025.

This year, our focus remains on identifying the impact that new data and treatments have on best practice, and how to translate these into your daily clinical practice in order to improve patient management.

To achieve this, we have brought together an international multidisciplinary top faculty to present the data, along with a panel of experts who will shape these data into recommendations on the spot, in a discussion-based format where you will also have a voice!

Yes, in only one and a half days, you will:

- **get a full update on prostate cancer**
- **learn from keynote speakers about the major clinical advances for your practice**
- **get the chance to interact and challenge the expert panel during case discussions**
- **share a coffee and your views with top leaders**

Join the discussions and participate in the lively discussions! Ready, set, go!

Welcome to Lisbon!

Share your photos
and thoughts on **X**
@mirrorsmed
#PROSCA25



Global organising committee



V rane Achard
Radiation Oncology
Bordeaux, France and
Geneva, Switzerland



Bertrand Tombal
Urology
Brussels, Belgium



Amit Bahl
Clinical Oncology
Bristol, UK

Local organising committee



Lu s Costa / Raquel Br s
Medical Oncology
Lisbon, Portugal



Carla Lopes de Castro
Radiation Oncology
Porto, Portugal



Arnaldo Figueiredo
Urology
Coimbra, Portugal



Kris Maes
Urology
Lisbon, Portugal



M rio Fontes-Sousa
Medical Oncology
Lisbon, Portugal



**Jos  Lu s Passos
Coelho / Joana Duarte
Albuquerque**
Medical Oncology
Lisbon, Portugal

Faculty

Vérane Achard

Radiation Oncology
Bordeaux, France and
Geneva, Switzerland

Amit Bahl

Clinical Oncology
Bristol, UK

Raquel Brás

Medical Oncology
Lisbon, Portugal

Eva Compérat (virtual)

Pathology
Vienna, Austria

Luis Costa

Medical Oncology
Lisbon, Portugal

Alan Dal Pra (virtual)

Radiation Oncology
Miami, USA

Maria De Santis

Medical Oncology
Berlin, Germany

Mário Fontes-Sousa

Medical Oncology
Lisbon, Portugal

Valérie Fonteyne

Radiation Oncology
Ghent, Belgium

Silke Gillesssen

Medical Oncology
Bellinzona, Switzerland

Karolien Goffin

Nuclear Medicine
Leuven, Belgium

Petros Grivas

Medical Oncology
Seattle, USA

Peter Hoskin

Clinical Oncology
Northwood & Manchester &
London, UK

Rob Jones

Medical Oncology
Glasgow, UK

Badrinath Konety

Urology
Minneapolis, USA

Carla Lopes de Castro

Radiation Oncology
Porto, Portugal

Kris Maes

Urology
Lisbon, Portugal

David Olmos

Medical Oncology
Madrid, Spain

Aurelius Omlin

Medical Oncology
Zürich, Switzerland

Henning Plage

Urology
Berlin, Germany

Daniele Raggi

Medical Oncology
London, UK

Jayne Tierney

Researcher
London, UK

Derya Tilki

Urology
Hamburg, Germany

Bertrand Tombal

Urology
Brussels, Belgium

Léa Turpin

Nuclear Medicine
Suresnes, France

Julien Van Damme

Urology
Brussels, Belgium

Roderick van den Bergh

Urology
Rotterdam, The Netherlands

Inge van Oort (virtual)

Urology
Groningen, The Netherlands

Nuno Vau

Medical Oncology
Lisbon, Portugal

Ursula Vogl

Medical Oncology
Bellinzona, Switzerland

Jochen Walz

Urology
Marseille, France

Thomas Zilli

Radiation Oncology
Bellinzona, Switzerland



Friday 5 December

09:15	Industry-sponsored satellite symposium
10:15	Break
11:00	Official opening Luís Costa, Carla Lopes de Castro
11:15	Unfavourable intermediate- and high-risk PCa Moderators: V��rane Achard, Carla Lopes de Castro Treatment challenges in clinical practice: What do you tell your patients? - Peter Hoskin, Jochen Walz Treatment strategies for elderly with locally advanced PCa - Bertrand Tombal Genomic classifiers: PCa risk redefined? - Alan Dal Pra (live remote) Panel discussion and Q&A
12:30	Update lecture: Precision strategies in mHSPC: State of the art and future directions Moderator: M��rio Fontes-Sousa Optimising outcomes in mHSPC: Current treatment approaches - Nuno Vau Genomic insights and emerging therapies in mHSPC - David Olmos Discussion and Q&A
13:00	Lunch
14:00	Case discussion session: Biochemical recurrence Moderators: Roderick van den Bergh, Jochen Walz Panel: V��rane Achard, Carla Lopes de Castro, Val��rie Fonteyne, Peter Hoskin, Derya Tilki, Bertrand Tombal, Julien Van Damme, Roderick van den Bergh, Inge van Oort, Jochen Walz Mirrors of Medicine – case-based approach - Bertrand Tombal Case presentation - Raquel Br��s, Henning Pl��ge Defining, imaging and managing BCR - Derya Tilki PSA-only monitoring in BCR: Who qualifies? - Julien Van Damme Optimising treatment in high-risk BCR patients - V��rane Achard Panel discussion and Q&A

Friday 5 December

15:30	Update lecture: Balancing margins and potency recovery in PCa surgery Moderator: Julien Van Damme Presenter: Kris Maes
16:00	Break
16:30	Case discussion session: mHSPC Moderators: Maria De Santis, Ursula Vogl Panel: Amit Bahl, Luís Costa, Maria De Santis, David Olmos, Aurelius Omlin, Daniele Raggi, Bertrand Tombal, Julien Van Damme, Roderick van den Bergh, Ursula Vogl, Thomas Zilli Case presentation - Raquel Brás, Henning Plage mHSPC – who needs radiotherapy? - Thomas Zilli mHSPC – who needs treatment intensification? - Daniele Raggi Treatment de-escalation in mHSPC - Bertrand Tombal The STOPCAP M1 Initiative: How systematic reviews can influence patient management - Jayne Tierney How to approach an mHSPC patient: Insights from clinical practice - Amit Bahl Panel discussion and Q&A
18:05	End of day 1 & reception



Saturday 6 December

08:25	Opening day 2
08:30	<p>Case discussion session: CRPC Moderators: Luís Costa, Rob Jones Panel: Amit Bahl, Raquel Brás, Luís Costa, Mário Fontes-Sousa, Silke Gillessen, Rob Jones, David Olmos, Aurelius Omlin, Inge van Oort, Ursula Vogl</p> <p>Case presentation - Raquel Brás, Henning Plage</p> <p>Combination approaches in first-line CRPC - Bertrand Tombal</p> <p>Targeting CRPC with PARPi & immunotherapy - Aurelius Omlin</p> <p>Targeting CRPC with radioligands - Karolien Goffin</p> <p>Sequential approaches with ARPI and chemotherapy in CRPC - Amit Bahl</p> <p>Patient-centred care in CRPC - Ursula Vogl</p> <p>Panel discussion and Q&A</p>
10:05	<p>Update lecture: Will AI replace the physician in PCa treatment? Moderator: Jochen Walz Presenter: Badrinath Konety</p>
10:30	Break
11:00	<p>Update lecture: Molecular diagnostics in motion: Liquid biopsies and tissue testing in mCRPC Moderator: Derya Tilki Presenter: David Olmos</p>
11:30	<p>APCCC Diagnostics 2025 highlights Moderators: Silke Gillessen, Aurelius Omlin Panel: Derya Tilki, Bertrand Tombal, Léa Turpin, Thomas Zilli</p> <p>Introduction - Silke Gillessen, Aurelius Omlin</p> <p>Discussion on APCCC Diagnostics 2025 questions</p>
12:30	Lunch
13:30	<p>Update lecture: The future of radioligands in PCa Moderator: Karolien Goffin Presenter: Léa Turpin Panel case discussion: Karolien Goffin, Bertrand Tombal, Léa Turpin</p>

Saturday 6 December

14:10

Looking ahead: PCa management in 2026

Moderator: Petros Grivas

View of the urologist - Roderick van den Bergh

View of the radiation oncologist - Thomas Zilli

View of the medical oncologist - Rob Jones

View of the pathologist - Eva Compérat (pre-recorded)

Discussion and Q&A

15:00

End of PROSCA



Check out our unique and free CME programmes in oncology

Translating new data from key congresses and
peer-reviewed papers into clinical practice



Interactive CME

The case-based Mirrors of Medicine™ learning method is highly interactive and integrates scientific evidence and clinical expertise to appropriately apply new insights in clinical practice in a time-efficient manner. Our programmes focus on actual clinical topics where new evidence is having a major impact on best practice.



Faculty

Our programmes are selected and defined by international experts involved in clinical decision making based on educational needs in a specific disease area.



Online & in-person

To cater to individual learning preferences, both online (PinPoint Case Platform) as virtual (Abstract2Practice, Manuscript2Practice, webinars) or in-person (EACCME-accredited Global Forum) learning opportunities are available.



Oncology

Our oncology programmes mainly focus on bladder, breast and prostate cancer, and renal cell carcinoma.



Why not join your colleagues...it's free!

mirrorsmed.org



Certificate of attendance

- ❶ Go to **<https://library.mirrorsmed.org>** and log in using your personal credentials you received by email.
- ❷ Go to the section **“My certificates”** and **download** your certificate of attendance.

Certificate of accreditation

- ❶ Go to **<https://library.mirrorsmed.org>** and log in using your personal credentials you received by email.
- ❷ Go to the section **“My certificates”** and complete the PROSCA **evaluation form**.
- ❸ After completion, you can **download** your certificate of accreditation.
- ❹ Deadline to complete the evaluation form and download the certificate of accreditation: **31 May 2026**.



Go to **<https://library.mirrorsmed.org>**

X
Spread
the word
@mirrorsmed
#PROSCA25

Practical information



Onsite contacts

General information	Delphine Corsten	+32 497 75 14 51
Exhibitors & sponsors	Luc Van Ruysevelt	+32 476 25 82 94



Opening hours registration & information desk

Thursday 4 December 2025:	07:30-18:00
Friday 5 December 2025:	07:30-18:00
Saturday 6 December 2025:	07:30-14:00

Accreditation points



PROSCA 2025 - Global Forum on Prostate Cancer (13th edition), Lisbon & hybrid, Portugal 05/12/2025-06/12/2025,

has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **10.0** European

CME credits (ECMEC®).

Accreditation Statement: Each medical specialist should claim only those credits that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at <https://edhub.ama-assn.org/pages/applications>. Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

PROSCA thanks its sponsors and partners

Principal sponsor



Platinum & educational sponsors



Johnson&Johnson

Silver sponsor



Silver sponsor & educational sponsor



Bronze sponsor




Bronze & educational sponsor




Partners



Organised by  **ISSECAM**

Meeting
management by 

 **Mirrors
of medicine**



Navigating ADT Choices in Prostate Cancer: A Patient-Centric Approach

Friday 5 December 2025

9:15 am - 10:15 am, Auditorium

Join interactive
polling and
discussion

Faculty



Chairman
Bertrand Tombal
Brussels, Belgium



**Barbara Alicja
Jereczek-Fossa**
Milan, Italy



Rob Jones
Glasgow, UK



Aurelius Omlin
Zurich, Switzerland

Agenda

Introduction

Prof. Bertrand Tombal

James' Complaints: A prostate cancer patient with severe LUTS

Prof. Barbara Alicja Jereczek-Fossa

James' Dilemma: What is the optimal duration of combined endocrine therapy?

Dr. Aurelius Omlin

James' Journey: Navigating ADT after a heart attack

Prof. Rob Jones


Panel discussion & conclusion

Moderated by Prof. Bertrand Tombal

This promotional symposium is organised
and sponsored by Accord Healthcare Ltd.

accord

Full invitation
with speaker
biographies



SAVE THE DATE

Translating new data into clinical practice

Highlights of 2026

2-5 December 2026

Amsterdam, The Netherlands

RENALC'26

Global Forum on
Renal Cancer

BLADDR'26

Global Forum on
Bladder Cancer

PROSCA'26

Global Forum on
Prostate Cancer



Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

PROSCA'25

Global Forum on
Prostate Cancer

ALL SESSIONS ARE INTERACTIVE



ASK QUESTIONS & ANSWER POLLS VIA YOUR SMARTPHONE

Ask the faculty all your questions and participate in interactive voting via your smartphone.

**JOIN AT
SLIDO.COM
#PROSCA**

OR SCAN



WE LOOK FORWARD TO HEARING YOUR OPINION!